Friday, 28 April 2017

FDA approves Novartis' leukemia treatment

(Reuters) - The U.S. Food and Drug Administration on Friday approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML).


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)